AnaptysBio Inc
ANABAnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
Analytics
主に工業および宝飾用の金属です。市場が不況を予想し、生産が低下すると、価値は下がります。宝飾品業界からの需要も不安定です。現在、プラチナは金よりも安く、それで作られたアイテムはエリートと見なされません。
39.70 USD生産が消費をまかなえない場合、供給不足の脅威があります。物理的な金属の不足への恐れの中で、価格は上昇します。しかし、これが不況の予想とともに起こると、価格にはほとんど影響がありません。これは2008年と2023年に明確に見られました。
–配当利回り
–今年
去年
今四半期
前四半期
今年
去年
今四半期
前四半期
主要人物 ANAB
配当分析 ANAB
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–